Medicine & Life Sciences
Mantle-Cell Lymphoma
100%
B-Cell Chronic Lymphocytic Leukemia
85%
Leukemia, Myeloid, Chronic Phase
42%
PCI 32765
41%
Survival
32%
Rituximab
32%
Chimeric Antigen Receptors
29%
Protein-Tyrosine Kinases
28%
Agammaglobulinaemia Tyrosine Kinase
19%
B-Cell Lymphoma
18%
B-Lymphocytes
17%
Mutation
17%
Therapeutics
16%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
15%
T-Lymphocytes
15%
Dasatinib
15%
Cell- and Tissue-Based Therapy
14%
Cyclophosphamide
13%
ponatinib
12%
Hairy Cell Leukemia
11%
Cytogenetics
11%
Non-Hodgkin's Lymphoma
11%
Vincristine
10%
Lymphoma
10%
Neoplasms
10%
Imatinib Mesylate
9%
Lymphoma, Large B-Cell, Diffuse
9%
Drug Therapy
9%
fludarabine
9%
venetoclax
9%
CD19 Antigens
8%
Stem Cell Transplantation
8%
Dexamethasone
8%
Progression-Free Survival
8%
Enhancer of Zeste Homolog 2 Protein
8%
Recurrence
8%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7%
Systemic Mastocytosis
7%
Acute Myeloid Leukemia
7%
Hospital Distribution Systems
7%
Doxorubicin
7%
Second Primary Neoplasms
6%
Clinical Trials
6%
zanubrutinib
6%
Interleukin-17
6%
Immunotherapy
5%
Adoptive Immunotherapy
5%
Signal Transduction
5%
Propensity Score
5%